Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Neurala Biosciences

2 Drug Candidates

Neurala Biosciences is a Melbourne-based clinical-stage biotech developing second-generation DMT–harmala alkaloid neuromedicines for mental health and addiction. Emerging from over a decade of research at the University of Melbourne, their Phase 1 proof-of-concept study was published in Scientific Reports (2025). Lead candidate NBX-100 targets substance use disorder; NBX-200 targets depressive illness.

Drug Pipeline

2

NBX-100

DMT
Phase I
Substance Use Disorders (SUD)Alcohol Use Disorder (AUD)

Oral DMT–harmala alkaloid combination, medium duration (3–5 hrs). GMP manufacturing completed Jan 2026; Phase 1 PK/PD study to commence at CMAX Clinical Research.

NBX-200

DMT
Pre-clinical
Major Depressive Disorder (MDD)

Intranasal DMT–harmala formulation, short duration (30–50 min), for chronic depressive illness.

Quick Facts

Type
Private Biotech
Lead Stage
Phase I
Website
Visit